New research from the Royal College of Surgeons in Ireland has found that venetoclax, a medication currently approved for leukemia, provides benefits for patients with multiple myeloma when used in combination with another ...
Mar 25, 2024
0
3
A new research paper titled "ABT199/venetoclax synergism with thiotepa enhances the cytotoxicity of fludarabine, cladribine and busulfan in AML cells" has been published in Oncotarget.
Mar 25, 2024
0
0
An existing blood cancer drug has shown promise in killing "silent" HIV cells in animal models and human cells from people living with HIV—a significant pre-clinical discovery that could lead to a cure for the disease.
Aug 31, 2023
0
21
A new editorial paper titled "Decoding the mechanism behind MCL-1 inhibitors: A pathway to understanding MCL-1 protein stability" has been published in Oncotarget.
Jun 28, 2023
0
2
First-line ibrutinib (Imbruvica) plus venetoclax (Venclexta) led to high response and survival rates in patients with chronic lymphocytic leukemia (CLL) whether or not their cancer harbored high-risk genetic features typically ...
Jun 7, 2023
0
3
Chemotherapy has been the most effective treatment to date for young and fit patients with chronic lymphocytic leukemia (CLL). The disease is the most common form of leukemia in the Western world, causing a substantial health ...
May 10, 2023
0
43
Targeted drugs have been developed to supplement chemotherapy in the treatment of cancer. These drugs only affect cancer cells, leaving healthy cells alone. Venetoclax is a new targeted therapy option for the treatment of ...
Feb 23, 2023
0
38
Acute myeloid leukemia (AML) is an aggressive form of cancer that originates in the bone marrow, rapidly spreads to the blood, and can quickly cause death if not treated promptly. Despite recent therapeutic advances, it continues ...
Feb 7, 2023
0
22
Combination therapies including venetoclax and another therapy have displayed promising results against subtypes of acute myeloid leukemia (AML) that are particularly difficult to treat, including relapsed or refractory AML ...
Dec 13, 2021
0
1
Researchers at Karolinska Institutet have investigated the use of low dose venetoclax, an experimental drug, for the treatment of the heterogeneous cancer disease multiple myeloma in patients who had relapsed on standard ...
May 19, 2021
0
27
